In vitro and in vivo studies of the action of rifampicin, clofazimine and B1912 on Mycobacterium marinum.
Rifampicin (RMP) and two riminophenazine compounds (B663 and B1912) suppressed the growth of Mycobacterium marinum in vitro and in a mouse footpad infection. At appropriate concentrations and dietary dosage, all three drugs showed bactericidal activity in vitro and in vivo. On the basis of minimum inhibitory concentration, RMP was considerably more active than the other two substances in vitro. However, the rate of bactericidal effect was similar for all three drugs. In vivo, the minimum bactericidal dietary dosages of RMP, B663 and B1912 were 0.03, 0.03 and less than or equal to 0.01%, respectively. Results suggest that these drugs may be of value for the treatment of clinical M. marinum infections.
D000818:Animals; D002991:Clofazimine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use / Q000031:analogs & derivatives; D051379:Mice; D009161:Mycobacterium / Q000187:drug effects*; D009164:Mycobacterium Infections / Q000188:drug therapy*; D010619:Phenazines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D010619:Phenazines; C012123:B1912; D002991:Clofazimine; D012293:Rifampin